Ing. Filip Rázga, Ph.D.

2013

• Mechanism of Impaired Glukose Metabolism during Nilotinib Therapy in Patients with Chronic Myelogenous Leukemia

  RÁČIL Zdeněk RÁZGA Filip DRÁPALOVÁ Jana BUREŠOVÁ Lucie ŽÁČKOVÁ Daniela PALACKOVÁ Martina SEMERÁD Lukáš MALÁŠKOVÁ Ludmila HALUZÍK Martin MAYER Jiří

  Conference abstract

  Year: 2013, type: Conference abstract

• Normal hematopoietic stem cells can be detected in newly diagnosed chronic myeloid leukemia patients and leukemic stem cells can be detected in CML patients after therapy by a multi-technique approach using antigen CD26.

  BORSKÝ Marek NÉMETHOVÁ Veronika RÁZGA Filip MAYER Jiří RÁČIL Zdeněk

  Conference abstract

  Year: 2013, type: Conference abstract

• Nuromuscular toxicity of tyrosine kinase inhibitors in the therapy of patients with chronic myeloid leukemia

  ZMORAJ Vladimír ŽÁČKOVÁ Daniela RÁČIL Zdeněk MIČÁNKOVÁ B. SEMERÁD Lukáš RÁZGA Filip JURČEK Tomáš DVOŘÁKOVÁ Dana MAYER Jiří

  Conference abstract

  Year: 2013, type: Conference abstract

• Quantitative detection of an IDH2 mutation for minimal residual disease monitoring in acute myeloid leukemia patients and its comparison with mutations in the NPM1 gene

  JEŽÍŠKOVÁ Ivana RÁZGA Filip TOŠKOVÁ Martina DVOŘÁKOVÁ Dana TIMILSINA Shira MAYER Jiří RÁČIL Zdeněk

  Article in Periodical

  Leukemia & Lymphoma, year: 2013, volume: 54, edition: 4, DOI

• Skin adverse effects of tyrosine kinase inhibitors in the therapy of patients with chronic myeloid leukemia - single centre experience

  ŽÁČKOVÁ Daniela RÁČIL Zdeněk KOVACEVICOVA Milica FEIT J. DOBEŠOVÁ Barbora PALACKOVÁ Martina JURČEK Tomáš RÁZGA Filip DVOŘÁKOVÁ Dana MAYER Jiří

  Conference abstract

  Year: 2013, type: Conference abstract

• Surface antigen CD26 as a marker for purification of CML stem cells

  BORSKÝ Marek NÉMETHOVÁ Veronika RÁZGA Filip MAYER Jiří RÁČIL Zdeněk

  Year: 2013, type:

• The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.

  MALČÍKOVÁ Jitka RÁZGA Filip JURČEK Tomáš DVOŘÁKOVÁ Dana ŽÁČKOVÁ Daniela TOŠKOVÁ Hana ŠEBEJOVÁ Ludmila ŠMARDOVÁ Jana OLTOVÁ Alexandra VAŇKOVÁ Gabriela JURAČKOVÁ Lenka TRBUŠEK Martin POSPÍŠILOVÁ Šárka MAYER Jiří RÁČIL Zdeněk

  Article in Periodical

  Leukemia & Lymphoma, year: 2013, volume: 54, edition: 9, DOI

• The prospective analysis of low level BCR-ABL1 T315I mutation in the CD34+ cells of de novo CML patients

  JURČEK Tomáš RÁZGA Filip MAZANCOVÁ Petra DVOŘÁKOVÁ Dana BORSKÝ Marek ŽÁČKOVÁ Daniela MUSILOVÁ M. SEMERÁD Lukáš MAYER Jiří RÁČIL Zdeněk

  Conference abstract

  Year: 2013, type: Conference abstract

2012

• Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing Detection of the T315I Mutation in Bone Marrow CD34+Cells of a Patient with Chronic Myelogenous Leukemia 6 Months Prior to its Emergence in Peripheral Blood

  RÁZGA Filip JURČEK Tomáš JEZISKOVA Ivana ŽÁČKOVÁ Daniela DVOŘÁKOVÁ Dana BORSKÝ Marek MAYER Jiří RÁČIL Zdeněk

  Article in Periodical

  Molecular Diagnosis & Therapy, year: 2012, volume: 16, edition: 3, DOI

• BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.

  ŠIMARA Pavel PETERKOVÁ Martina STEJSKAL Stanislav POTĚŠILOVÁ Michaela KRONTORÁD KOUTNÁ Irena RÁČIL Zdeněk RÁZGA Filip JURČEK Tomáš DVOŘÁKOVÁ Dana MAYER Jiří

  Article in Periodical

  Leukemia & lymphoma, year: 2012, volume: 53, edition: 8, DOI